September 25, 2008 – Proton therapy (a specialized type of external beam radiation therapy using protons rather than X-rays to treat cancer) decreases the risk of patients developing a secondary cancer by two-fold, compared to being treated with standard photon radiation treatment, according to a first-of-its-kind study presented Sept. 22, 2008, at the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston.

This study contradicts recent theories that have suggested that proton radiation might actually increase — instead of decrease — the incidence of secondary cancers because of what is called scatter radiation. When proton radiation is delivered, neutrons are produced by nuclear interactions and are therefore scattered as a result.

“This study could have a substantial impact on the care of patients,” Nancy Tarbell, M.D., senior author of the study and a radiation oncologist at the Massachusetts General Hospital in Boston, said. “Since cancer patients are surviving for longer periods of time, side effects of therapy are becoming increasingly important for doctors to consider when developing treatment plans. Since this is a retrospective study, however, we will need additional studies to further prove this hypothesis.”

This study contradicts recent theories that have suggested that proton radiation might actually increase - instead of decrease - the incidence of secondary cancers because of what is called scatter radiation. When proton radiation is delivered, neutrons are produced by nuclear interactions and are therefore scattered as a result.

Photon radiation is the standard external beam radiation therapy treatment, while proton radiation is a more targeted form of external beam radiation, which delivers less radiation to bordering normal structures. During external beam radiation therapy, a beam of radiation is directed through the skin to the cancer and the immediate surrounding area in order to destroy the main tumor and any nearby cancer cells. The retrospective cohort study matched 503 patients who underwent Harvard Cyclotron proton radiation treatment with 1,591 patients treated with photon radiation therapy from the Surveillance, Epidemiology and End Results (SEER) cancer registry from 1974 to 2001. According to the study, 6.4 percent of patients who underwent proton therapy developed a secondary cancer while 12.8 percent of patients who had photon treatment developed another type of cancer.

For more information: www.rtanswers.org and www.astro.org


Related Content

News | Radiology Business

May 20, 2024 — Associated Medical Professionals of NY (A.M.P.) announced that internationally recognized radiation ...

Time May 20, 2024
arrow
News | Artificial Intelligence

May 14, 2024 — Elekta announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high ...

Time May 14, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Insurance expansions under the Affordable Care Act (ACA) were linked with an increase in patients ...

Time May 10, 2024
arrow
News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Subscribe Now